Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease

NCT03000569 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03000569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03000569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
September 11, 2017
Enrollment
29 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease